192 related articles for article (PubMed ID: 24512717)
1. Use of plerixafor for peripheral blood stem cell mobilization failure in children.
Emir S; Demir HA; Aksu T; Kara A; Özgüner M; Tunç B
Transfus Apher Sci; 2014 Apr; 50(2):214-8. PubMed ID: 24512717
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.
Vives S; Sancho JM; Almazán F; Juncà J; Grifols JR; Ribera JM
J Clin Apher; 2012 Nov; 27(5):260-2. PubMed ID: 22566276
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Acta Haematol; 2016; 135(1):29-36. PubMed ID: 26303343
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
[TBL] [Abstract][Full Text] [Related]
7. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
11. Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor.
Zucenka A; Peceliunas V; Maciutaite E; Chaleckaite J; Jakimaviciute R; Griskevicius L
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1304-1311. PubMed ID: 30871977
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.
Kim JS; Yoon DH; Park S; Yoon SS; Cho SG; Min CK; Lee JJ; Yang DH; Kwak JY; Eom HS; Kim WS; Kim H; Do YR; Moon JH; Lee J; Suh C
Ann Hematol; 2016 Mar; 95(4):603-11. PubMed ID: 26754633
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L; Laszlo D; Rizzi S; Balzarotti M; Antoniazzi F; Zilioli VR; Guggiari E; Farina L; Todisco E; Bonfichi M; Alamos SM; Rossi G; Martinelli G; Morra E
Leuk Res; 2011 Jun; 35(6):712-4. PubMed ID: 21276613
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
17. Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers.
Bilgin YM; Gahar RR; Visser O; Croockewit A; de Greef GE
Transfus Apher Sci; 2013 Apr; 48(2):191. PubMed ID: 23809830
[No Abstract] [Full Text] [Related]
18. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.
Avramova BE; Yordanova MN; Konstantinov DN; Bobev DG
Drug Des Devel Ther; 2011; 5():407-9. PubMed ID: 21966213
[TBL] [Abstract][Full Text] [Related]
19. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
